



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/621,329	07/18/2003	Toshihiro Mori	2870-0260P	2530
2292	7590	01/10/2007	EXAMINER	
BIRCH STEWART KOLASCH & BIRCH			BABIC, CHRISTOPHER M	
PO BOX 747			ART UNIT	PAPER NUMBER
FALLS CHURCH, VA 22040-0747			1637	
SHORTENED STATUTORY PERIOD OF RESPONSE		NOTIFICATION DATE	DELIVERY MODE	
3 MONTHS		01/10/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice of this Office communication was sent electronically on the above-indicated "Notification Date" and has a shortened statutory period for reply of 3 MONTHS from 01/10/2007.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Office Action Summary	Application No.	Applicant(s)
	10/621,329	MORI ET AL.
	Examiner Christopher M. Babic	Art Unit 1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 9/22/2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,2 and 4-20 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1,2 and 4-20 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of the Claims

Claims 1, 2, and 4-20 are pending. The following Office Action is in response to Applicant's response dated September 22, 2006.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 8 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The specification has not taught how to make or use a non-porous surface saponified cellulose acetate membrane within the methods as required by claim 7. Cellulose acetate membranes, inherently, are porous membranes. The specification does not provide any working examples of non-porous cellulose acetate membranes. Furthermore, the state of the art suggests that porous membranes are traditionally used

for the isolation of nucleic acid (see the applied art below). It would require inventive and undue experimentation in order to determine how to provide such a non-porous surface saponified cellulose acetate membrane for the practice of the claimed invention since none are known to exist. Therefore, it is concluded that it would require undue experimentation to practice the claimed invention.

Claim Rejections - 35 USC § 103

The rejections of claim(s) 1, 2, 9, 12, and 14 over Mullis in view of Nagamatsu have been withdrawn in view of Applicant's amendment.

The rejections of claim(s) 1, 2, 9, 10, and 12-15 over Woodward in view of Nagamatsu have been withdrawn in view of Applicant's amendment.

The rejections of claim(s) 3-7 over Woodward in view of Nagamatsu, in further view of Morishita have been withdrawn in view of newly discovered reference(s).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation

under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The following new ground(s) of rejection is made in view of newly discovered reference(s).

1. Claims 1, 2, 7, 9, 12, and 14-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mullis (U.S. 5,187,083) as evidenced by GE Osmonics (<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes") in view of Bryk et al. ("Porous structure of cellulose acetate ultrafiltration membranes of various degrees of saponification" Polymer Science U.S.S.R., Volume 32, Issue 7, 1990, Pages 1401-1409).

Regarding claim 1, Mullis discloses a method for separating and purifying a nucleic acid from a biological sample comprising the step of: adsorbing and desorbing a nucleic acid to and from a membrane of an organic macromolecule (col. 10, ex. 4, for example). Specifically, Mullis teaches the capture and elution of DNA from blood on cellulose acetate membrane filters (col. 10, lines 20-30, for example). The membrane referenced in example 4 of Mullis is a 0.45 micron, 2.5 cm diameter, from MSI, Inc. (col. 10, lines 20-25, for example). It is submitted that MSI, Inc. is a division of GE Osmonics

(see printout of <http://www.tcn.zaq.ne.jp/membrane/english/MembManufE.htm>, "Websites of Membrane Manufacturers", pg. 5, for example). Ge Osmonics provides cellulose acetate membrane of 0.45 micron, 2.5 cm diameter, and a thickness of 65-110 μm (see printout of <http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes", pg. 4, for example). It is submitted that the cellulose acetate membranes taught by Mullis are necessarily within the thickness of 10-500 μm as required by the claimed invention.

Regarding claim 2, a cellulose acetate necessarily has a degree of hydroxyl groups on the surface thereof.

Regarding claim 7, Mullis teaches porous cellulose acetate membranes (col. 5, lines 35-50, for example).

Regarding claim 9, Mullis teaches nucleic acid a sample solution (col. 10, ex. 4, for example).

Regarding claim 12, Mullis discloses washing the membrane with a nucleic acid washing buffer after adsorbing and then desorbing the nucleic acid from the membrane with a solution capable of desorbing the nucleic acid from the membrane (ex. 3, for example).

Regarding claim 14, the desorbing solution has a salt concentration of 0.5 M or less (ex. 3, for example).

With regard to claim 15 and 16, Mullis teaches a method wherein adsorption and desorption of the nucleic acid is performed by use of a unit for isolation and purification

Art Unit: 1637

comprising (a) a membrane of the organic macromolecule; (b) a container having at least two openings and containing the membrane; and (c) a differential pressure generator connected to one opening of the container. Specifically, Mullis teaches an example wherein the adsorption and desorption of the nucleic acid is performed within a vacuum-filtration device which is a container with at least two openings and which contained a cellulose acetate membrane filter (ex. 4, for example). Further, the vacuum filtration device inherently would be connected to a differential pressure generator (i.e. the vacuum) that is connected to an opening of the device.

Mullis does not expressly teach surface saponification of cellulose acetate membranes.

Bryk et al. provides a supporting disclosure that teaches of the effects of saponification on cellulose acetate membranes (abstract; pgs. 1408-1409, for example). They expressly teach that upon saponification of cellulose acetate membranes, among other physical changes, the rigidity of the membrane increases (pg. 1408, para. 3-end; pg. 1409, for example).

It would have been *prima facie* obvious for a practitioner of ordinary skill in the art at the time of invention to apply saponification procedures to the membranes taught by Mullis to increase the membrane rigidity therefore decreasing the likelihood of physical degradation of the membrane, thus arriving at the claimed invention.

The following new ground(s) of rejection is made in view of newly discovered reference(s).

2. Claims 1, 2, 4-7, 9, 12, and 14-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mullis (U.S. 5,187,083) as evidenced by GE Osmonics (<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes") in view of Tuccelli et al. (U.S. 5,522,991).

Regarding claim 1, Mullis discloses a method for separating and purifying a nucleic acid from a biological sample comprising the step of: adsorbing and desorbing a nucleic acid to and from a membrane of an organic macromolecule (col. 10, ex. 4, for example). Specifically, Mullis teaches the capture and elution of DNA from blood on cellulose acetate membrane filters (col. 10, lines 20-30, for example). The membrane referenced in example 4 of Mullis is a 0.45 micron, 2.5 cm diameter, from MSI, Inc. (col. 10, lines 20-25, for example). It is submitted that MSI, Inc. is a division of GE Osmonics (see printout of <http://www.tcn.zaq.ne.jp/membrane/english/MembManufE.htm>, "Websites of Membrane Manufacturers", pg. 5, for example). Ge Osmonics provides cellulose acetate membrane of 0.45 micron, 2.5 cm diameter, and a **thickness of 65-110 µm** (see printout of <http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes", pg. 4, for example). It is submitted that the cellulose acetate membranes taught by Mullis are necessarily within the thickness of 10-500 µm as required by the claimed invention.

Regarding claim 2, a cellulose acetate necessarily has a degree of hydroxyl groups on the surface thereof.

Regarding claim 9, Mullis teaches nucleic acid a sample solution (col. 10, ex. 4, for example).

Regarding claim 12, Mullis discloses washing the membrane with a nucleic acid washing buffer after adsorbing and then desorbing the nucleic acid from the membrane with a solution capable of desorbing the nucleic acid from the membrane (ex. 3, for example).

Regarding claim 14, the desorbing solution has a salt concentration of 0.5 M or less (ex. 3, for example).

With regard to claim 15 and 16, Mullis teaches a method wherein adsorption and desorption of the nucleic acid is performed by use of a unit for isolation and purification comprising (a) a membrane of the organic macromolecule; (b) a container having at least two openings and containing the membrane; and (c) a differential pressure generator connected to one opening of the container. Specifically, Mullis teaches an example wherein the adsorption and desorption of the nucleic acid is performed within a vacuum-filtration device which is a container with at least two openings and which contained a cellulose acetate membrane filter (ex. 4, for example). Further, the vacuum filtration device inherently would be connected to a differential pressure generator (i.e., the vacuum) that is connected to an opening of the device.

Mullis does not expressly teach surface saponification of cellulose acetate membranes.

Tuccelli et al. provides a supporting disclosure that teaches cellulosic membranes having a surface saponified ultrafiltration layer (col. 3; ex. 1-3, for example). They expressly teach a membrane with a 11 µm saponified layer of cellulose (col. 6, lines 1-10, for example).

With regard to claim 4, Tuccelli teaches surface-saponified triacetylcellulose (col. 3, lines 55-65, for example).

With regard to claims 5 and 6, Tuccelli teaches saponification rates of 5% or higher (col. 5, lines 40-45, for example).

With regard to claim 7, Tuccelli teaches porous cellulose acetate membranes (col. 3, lines 40-45, for example).

Tuccelli further teaches that their cellulose membranes are resistant to high-back pressures as compared to those cellulose membranes of the prior art (col. 3, lines 30-35; table 1, for example)

It would have been *prima facie* obvious for a practitioner of ordinary skill in the art at the time of invention to incorporate the membranes of Tuccelli into the methods of Mullis since the membranes of Tuccelli are resistant to high-back pressures, thus arriving at the claimed invention.

The following new ground(s) of rejection is made in view of newly discovered reference(s).

3. Claims 10 and 11^{are} rejected under 35 U.S.C. 103(a) as being unpatentable over Mullis (U.S. 5,187,083) as evidenced by GE Osmonics (<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes") in view of Bryk et al. ("Porous structure of cellulose acetate ultrafiltration membranes of various degrees of saponification" Polymer Science U.S.S.R., Volume 32, Issue 7, 1990, Pages 1401-1409) as applied to claims 1, 2, 7, 9, 12, and 14-16 above, or Tuccelli et al. (U.S. 5,522,991) as applied to claims 1, 2, 4-7, 9, 12, and 14-16 above, and in further view of Kuroita et al. (U.S. 5,990,302).

With regard to claims(s) 10 and 11, the methods of the previously applied reference(s) have been outlined in the above rejections. Mullis teaches using "typical" procedures for obtaining DNA from samples (col. 5, lines 10-30, for example), however, does not expressly disclose a reagent set comprising a water-soluble organic solvent, guanidine salt, a surfactant, and a protease.

Kuroita teaches that target nucleic acid molecules are released from cells by treatment with a reagent set comprising a water-soluble organic solvent, guanidine salt, a surfactant, and a protease (col. 7, line 50-col. 8, line 15, for example).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have modified the methods taught by Mullis so as to have utilized a lysis buffer that included reagents that are typically considered lysis agents for the release of nucleic acids from sample cells. One would have been

motivated by the teachings of Mullis to use any such typical methodologies for obtaining lysis solutions, such as those exemplified by the teachings of Kuroita. It would have been *prima facie* obvious for one of ordinary skill in the art at the time of invention to practice the methods as claimed.

5. Claims 17 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mullis (U.S. 5,187,083) as evidenced by GE Osmonics (<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes") in further view of Heath et al. (WO 99/13976).

Regarding claims 17 and 18, the methods of the previously applied references have been outlined in the above rejections. The previously applied references do not expressly teach the sequence of steps required in claims 17 and 18 wherein fluids are brought into contact with the membrane by inserting one opening of a unit for isolation and purification into a fluid (first sample, second washing buffer, third desorbing solution), creating a reduced pressure in a container by a differential pressure generator to suck the fluid into the chamber and into contact with the hydroxyl group, and creating an increased pressure within the chamber which results in discharge of the fluid from the chamber. Claim 17 requires the repetition of these steps for three different fluids, while claim 18 requires the repetition of these steps for only the sample and the desorbing solution.

Heath discloses methods for isolation of nucleic acid from samples and teaches automated steps of loading a sample into a container with at least two openings (pg. 7, lines 11-12, for example), loading a wash into the container (pg. 7, lines 13-17, for example), and loading desorbing buffer (referred to as elution buffer) into the container (pg. 7, lines 18-23, for example). Heath discloses the use of vacuum pumps for the movement of solutions into and out of the isolation chamber (pg. 8, lines 6-14; 21-22, for example). Heath specifically teach that methods in which the sample is loaded via aspiration which occurs via the insertion of the opening of the chamber into the sample and the application of negative pressure to suck the sample into the chamber (p. 10, exemplified pg. 23, for example). Further, Heath teaches methods in which the gases are pumped into the chamber which increases pressure in the chamber and

It would have been *prima facie* obvious to one of ordinary skill in the art to have applied the sample processing methodologies taught by Heath to the methods taught by applied references since Heath suggests such methodologies for automation of sample processing.

The following new ground(s) of rejection is made in view of newly discovered reference(s).

6. Claims 19 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mullis (U.S. 5,187,083) as evidenced by GE Osmonics (<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA

(Cellulose Acetate) Membranes") in view of Heath et al. (WO 99/13976) as applied to claims 17 and 18 above, and in further view of Bryk et al. ("Porous structure of cellulose acetate ultrafiltration membranes of various degrees of saponification" Polymer Science U.S.S.R., Volume 32, Issue 7, 1990, Pages 1401-1409).

With regard to claims 19 and 20, Mullis does not expressly teach surface saponification of cellulose acetate membranes.

Bryk et al. provides a supporting disclosure that teaches of the effects of saponification on cellulose acetate membranes (abstract; pgs. 1408-1409, for example). They expressly teach that upon saponification of cellulose acetate membranes, among other physical changes, the rigidity of the membrane increases (pg. 1408, para. 3-end; pg. 1409, for example).

It would have been *prima facie* obvious for a practitioner of ordinary skill in the art at the time of invention to apply saponification procedures to the membranes taught by Mullis to increase the membrane rigidity therefore decreasing the likelihood of physical degradation of the membrane, thus arriving at the claimed invention.

The following new ground(s) of rejection is made in view of newly discovered reference(s).

7. Claims 19 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mullis (U.S. 5,187,083) as evidenced by GE Osmonics

(<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes") in view of Heath et al. (WO 99/13976) as applied to claims 17 and 18 above, and in further view of Tuccelli et al. (U.S. 5,522,991).

With regard to claims 19 and 20, Mullis does not expressly teach surface saponification of cellulose acetate membranes.

Tuccelli et al. provides a supporting disclosure that teaches cellulosic membranes having a surface saponified ultrafiltration layer (col. 3; ex. 1-3, for example). They expressly teach a membrane with a 11 µm saponified layer of cellulose (col. 6, lines 1-10, for example).

It would have been *prima facie* obvious for a practitioner of ordinary skill in the art at the time of invention to incorporate the membranes of Tuccelli into the methods of Mullis since the membranes of Tuccelli are resistant to high-back pressures, thus arriving at the claimed invention.

Response to Arguments - Claim Rejections - 35 USC § 103

Applicant's Declaration under 37 C.F.R 1.132 has been considered but is moot in view of the new ground(s) of rejection.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11

Art Unit: 1637

F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

1. Claims 1-18 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over: 1) claims 1-18 of copending Application 10/209,336; 2) claims 1-2 of copending Application 10/305,110; 3) claims 1-18 of copending Application No. 10/621,412; 4) claims 1-20 of copending Application No. 10/621,715, and; 5) claims 1-35 of copending Application 10/975,469 in view of Mullis (U.S. 5,187,083) as evidenced by GE Osmomics (<http://www.osmolabstore.com/OsmoLabPage.dll?BuildPage&1&1&897>, "GE CA (Cellulose Acetate) Membranes").

An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29

USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F. 2d 887, 225 USPQ 645 (fed. Cir. 1985).

Although the conflicting claims are not identical, they are not patentably distinct from each other because each set of claims is drawn to a method for separating and purifying a nucleic acid wherein each method encompasses the same general inventive concept of adsorbing and desorbing a nucleic acid onto an surface saponified acetylcellulose solid phase.

It would have been *prima facie* obvious to incorporate a membrane (i.e. solid phase) with the broad thickness range of the claimed invention. The inclusion of this limitation is well within the range of ordinary skill in the art as demonstrated, for example, by Mullis (ex. 4, for example).

These are provisional obviousness-type double patenting rejections because the conflicting claims have not in fact been patented.

Response to Arguments - Double Patenting

Applicant's arguments with respect to the ODP rejections have been fully considered but are not persuasive. A "provisional" ODP rejection is not the only rejection remaining in the instant application. Thus, the ODP rejections have been maintained.

Conclusion


Claims 1, 2, and 4-20 are rejected. No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher M. Babic whose telephone number is 571-272-8507. The examiner can normally be reached on Monday-Friday 7:00AM to 4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christopher M. Babic
Patent Examiner
AU 1637

 12/18/06


KENNETH R. HORLICK, PH.D.
PRIMARY EXAMINER

12/20/06